Inside California's Contingency Plan: How Abortion Pill Suppliers Are Preparing for Life After a Supreme Court Mifepristone Ruling

On May 1, 2026, a three-judge panel of the U.S. Court of Appeals for the Fifth Circuit granted Louisiana's request to reimpose in-person dispensing requirements for mifepristone — the first drug in a two-drug regimen used in roughly 65% of all U.S. abortions [1]. The ruling took effect immediately and applied nationwide, halting mail-order distribution and telehealth prescribing of the medication that approximately 7.5 million women have used since its FDA approval in 2000 [2].

Three days later, Justice Samuel Alito issued a one-week administrative stay, temporarily restoring access while the full Court considered the emergency appeal [3]. That stay expires May 11, and the justices have not signaled whether they will extend it or allow the Fifth Circuit's order to take hold [4].

In California, suppliers did not wait to find out.

"We heard about this on Friday and organizations that mail pills were mailing misoprostol on Saturday," said Dr. Michele Gomez, co-founder of the MYA Network, a California-based organization that trains clinicians in abortion care. "They already knew what to do" [5].

The Scale of What's at Stake

Medication abortion has risen from 24% of all U.S. abortions in 2011 to 65% in 2024, according to the Guttmacher Institute [6]. In California specifically, the Guttmacher Institute estimated that 183,720 abortions were performed in the state in 2024, with approximately 71% — roughly 130,000 — being medication abortions [7].

Source: Guttmacher Institute

Data as of Mar 1, 2025CSV

A quarter of all U.S. abortions are now obtained via telehealth, half of which are provided to patients in states with abortion bans or significant restrictions [8]. According to the Society of Family Planning's #WeCount project, an estimated 55% of telehealth medication abortions in June 2025 were provided to patients in states with abortion restrictions [1]. Reimposing in-person dispensing requirements would disrupt access not only for patients in ban states who rely on out-of-state telehealth, but also for patients in permissive states who use the mail-order option for convenience or privacy.

California's Legal Arsenal

California has constructed what may be the most aggressive state-level legal infrastructure to protect medication abortion access, anchored by several overlapping mechanisms.

AB 260 (Shield Law). Signed by Governor Gavin Newsom in October 2025, this law permits prescribers and pharmacies to omit the name of the patient, the prescriber, or the pharmacy from mifepristone packaging [9]. It shields pharmacists from criminal, civil, or professional penalties when they manufacture, transport, or handle medication abortion drugs. A confidential log of identifying information is accessible only to California law enforcement through a subpoena; out-of-state entities, including out-of-state law enforcement, are explicitly barred [9].

SB 345 and AB 1707. Enacted in 2023, these statutes protect California-based providers and facilities from enforcement of other states' laws that criminalize or restrict reproductive health care services [10].

Insurance mandates. AB 260 requires California-regulated health plans to cover mifepristone regardless of changes to its FDA approval status [9].

Anti-subpoena legislation (pending). A bill advancing through the California Legislature in 2026 would impose state fines on medical providers who comply with federal subpoenas seeking abortion care information without first notifying the California attorney general, patients, and providers [11].

The critical question is whether any of these state protections can withstand federal preemption. None of California's shield laws has been tested in a direct federal court challenge. If the Supreme Court rules that the FDA's 2023 REMS modification was procedurally invalid, California's mandate to cover mifepristone "regardless of FDA approval status" would face a collision with federal drug law that no state shield law was designed to resolve.

Compounding pharmacy exemptions represent another potential workaround. Under federal law, compounding pharmacies can produce medications under certain conditions even when the FDA-approved version faces restrictions. California has a robust compounding pharmacy sector, but whether this exemption could be used to produce mifepristone at scale remains legally untested [12].

The Misoprostol Fallback

The most immediate workaround is not legal but pharmacological: switching from the standard mifepristone-plus-misoprostol regimen to misoprostol alone.

The clinical tradeoffs are significant. The combination regimen — 200 mg of mifepristone followed by misoprostol 24-48 hours later — has a success rate of approximately 95-98% for pregnancies up to 10 weeks [2]. Misoprostol alone is less effective. A major randomized clinical trial found success rates of 79.1% for the combination versus 58.7% for misoprostol alone in managing early pregnancy loss [13]. The World Health Organization has stated that "mifepristone with misoprostol is more effective than misoprostol used alone, and is associated with fewer side-effects" [5].

The cost picture is counterintuitive. Although mifepristone costs approximately $83 per 200 mg tablet in the United States, a misoprostol-only regimen was found in one study to be 26% more expensive overall because failed treatments require follow-up interventions, including surgical procedures [14]. Mean medical costs per patient were €529 in the mifepristone group versus €664 in the misoprostol-only group [14].

Providers like Gomez have argued that misoprostol-only protocols, while inferior, are safe enough to maintain access in an emergency. The drug is widely available, inexpensive in its generic form, and used globally in settings where mifepristone is unavailable [5]. But reproductive health researchers caution that normalizing a less effective regimen could increase complication rates and emergency room visits — outcomes that would disproportionately affect patients without reliable follow-up care.

States vs. California Providers: The Enforcement Landscape

The legal conflict between restrictive states and California-based providers is no longer hypothetical. Louisiana became the first state to schedule mifepristone as a controlled substance and to criminally indict an out-of-state physician — Dr. Rémy Coeytaux, a Bay Area doctor — for allegedly prescribing and mailing abortion pills to a Louisiana woman in October 2023 [11]. Governor Newsom rejected Louisiana's extradition request [11].

This standoff tests a fundamental question of federalism. California's shield laws block cooperation with out-of-state enforcement, but they cannot prevent a restrictive state from issuing indictments or arrest warrants. Providers who cross state lines — for conferences, vacations, or family visits — could face arrest in states where they are charged.

The Trump administration has added a federal dimension to this conflict. Federal subpoenas seeking medical records from California institutions have already been issued in related healthcare contexts, and pending California legislation attempts to create procedural barriers to compliance [11]. Whether a state can legally instruct its residents to delay compliance with a federal subpoena is an open constitutional question.

The Administrative Law Argument Against FDA

The strongest legal argument for restricting mifepristone access does not rest on abortion politics but on administrative procedure.

Louisiana's case, Louisiana v. FDA, argues that the FDA violated the Administrative Procedure Act when it modified the mifepristone REMS in 2023 to remove in-person dispensing requirements [1]. The argument gained unexpected support when the Trump administration's FDA conceded in September 2025 that prior REMS approvals suffered from a "lack of adequate consideration" [1].

The Fifth Circuit resolved the standing question in Louisiana's favor, finding that the state demonstrated injury through increased Medicaid costs for emergency care related to mifepristone complications [1]. This is significant because in 2024, the Supreme Court rejected a similar challenge in Alliance for Hippocratic Medicine v. FDA, finding that anti-abortion doctors lacked standing to sue [15]. By granting standing to a state government rather than individual physicians, the Fifth Circuit identified a new plaintiff class that could survive judicial scrutiny.

Louisiana also invokes the Comstock Act of 1873, arguing that it "prohibits the mailing of any medication used for abortion" [1]. If the Supreme Court credits this argument, it could provide a statutory basis for banning mail distribution that operates independently of any FDA regulatory question.

Anti-abortion legal advocates, including Alliance Defending Freedom, have framed the FDA's 2023 decision as an example of regulatory overreach during the Biden administration — a politically motivated relaxation of safety standards that bypassed normal review processes [16]. They point to the FDA's own subsequent concession as evidence that the original decision was procedurally flawed.

The Pharmaceutical Industry's Broader Concern

The mifepristone case has drawn dozens of amicus briefs from entities with no direct stake in abortion policy. Nine former FDA commissioners, including Janet Woodcock and Robert Califf, filed a joint brief arguing that the Fifth Circuit's approach would "upend FDA's gold-standard, science-based drug approval system, and creates a roadmap for attacks on science-based regulatory decisions" [4].

Over 200 pharmaceutical companies, executives, and investors — including Biogen, Pfizer, and Gilead — filed briefs in the related 2024 case warning that allowing courts to second-guess FDA drug approvals would undermine investment in drug development [4]. The pharmaceutical industry's main lobbying group echoed this concern [4].

The worry extends beyond mifepristone. If the Court establishes that states can challenge FDA regulatory decisions through citizen petitions and litigation, vaccines, contraceptives, and other medications with contested political histories could face similar challenges [17]. The FDA's citizen petition process requires challengers to exhaust administrative remedies before litigating, with a six-year statute of limitations — but the mifepristone litigation has tested whether these procedural guardrails hold [18].

Source: OpenAlex

Data as of Jan 1, 2026CSV

Academic research on mifepristone and abortion has produced nearly 6,000 published papers, peaking at 687 in 2021 — the year the FDA began its comprehensive review that led to the REMS modification [19]. This body of evidence formed the basis for the FDA's conclusion that in-person dispensing was not medically necessary. Whether courts should defer to this scientific consensus or conduct independent review of the evidence is a central tension in the case.

Follow the Money

The Dobbs decision in June 2022 triggered a wave of investment in abortion telehealth. Hey Jane, a telemedicine abortion startup, secured a $6 million Series A round in late 2022, following a $3 million seed round [20]. Choix, a San Francisco-based telehealth company, received $1 million in seed funding from Elevate Capital and used it to expand beyond California, Colorado, and Illinois [20]. The California Health Care Foundation invested $250,000 in Twentyeight Health, which provides reproductive services to Spanish-speaking and rural women [21].

These financial flows raise a question that critics have surfaced: does venture capital investment in abortion telehealth companies create a financial interest that shapes those companies' public policy advocacy? The companies themselves argue that investment validates their model and expands access. Critics counter that for-profit telehealth companies have a business incentive to oppose regulations that would shrink their market, regardless of the medical merits [22].

Larger players have also entered the space. Carbon Health, valued at $3 billion after raising $350 million, has been outspoken in support of abortion rights [20]. The concentration of telehealth abortion providers in states with strong legal protections — primarily California and New York — means that any restriction on mail-order dispensing directly threatens the business model that attracted this investment.

Who Gets Left Behind

Even if California's workarounds succeed in maintaining access for some patients, significant gaps remain — gaps that track familiar lines of income, geography, insurance status, and documentation.

Undocumented immigrants face compounding barriers. Approximately 50% of likely undocumented immigrant adults are uninsured, compared with 8% of U.S.-born citizens [23]. U.S. Customs and Border Protection operates over 100 checkpoints within 100 miles of the southern border, creating obstacles that telehealth cannot solve when physical travel is required for follow-up care [23]. Only 16 states and the District of Columbia permit undocumented immigrants to obtain driver's licenses [23].

Low-income patients without insurance coverage face the full cost of medication and any required follow-up visits. A switch to less effective misoprostol-only protocols would increase the likelihood of complications requiring emergency care — care that uninsured patients may delay seeking due to cost.

Rural patients in California's Central Valley and northern regions may live hours from the nearest provider. While telehealth addresses the prescribing step, complications from medication abortion still require proximity to emergency services.

Language barriers compound each of these obstacles. Organizations like Twentyeight Health have begun providing services in Spanish, but outreach in other languages spoken by California's immigrant communities — including Mandarin, Tagalog, Vietnamese, and indigenous Mexican languages — remains limited [21].

Abortion funds have developed workarounds of their own, covering procedure costs, booking travel, and purchasing bus tickets along routes that avoid immigration checkpoints [23]. But these ad hoc solutions depend on philanthropic funding that could dry up as donor fatigue sets in or as legal risks increase.

What Happens Next

The Supreme Court faces a May 11 deadline to decide whether to extend Justice Alito's administrative stay of the Fifth Circuit ruling [3]. The options range from a brief extension while the Court considers the merits to an emergency decision on the full case.

If the Court allows the Fifth Circuit ruling to stand, in-person dispensing requirements would be reimposed nationwide, immediately disrupting telehealth and mail-order abortion access even in states where abortion is legal. California's shield laws and misoprostol fallback plans would face their first real-world test.

If the Court blocks the ruling, the underlying case — Louisiana v. FDA — continues through the lower courts and could return to the Supreme Court on the merits, likely in the 2026-2027 term.

The broader implications extend beyond abortion. The case will set a precedent for whether states can use the courts to override FDA drug approval decisions — a question that the pharmaceutical industry, regardless of its position on abortion, has a direct interest in seeing resolved in the FDA's favor. As one former FDA commissioner wrote in an amicus brief, "This case is not just about one drug. It is about whether the FDA's scientific judgment will continue to be the foundation of drug regulation in the United States" [4].